{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:51:46Z","timestamp":1768697506305,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>sphingosine-1-phosphate (S1P), a naturally occurring sphingolipid, has been involved in pulmonary interstitial remodeling signaling. However, no study has examined its clinical merits for interstitial lung disease (ILD). This study aimed to investigate the serum level of S1P in ILD patients and its clinical correlation with the severity of disease in the two main types of ILDs: the IPF and the CTD-ILD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational pilot study included 67 ILD patients and 26 healthy controls. These patients were stratified into the IPF group (35) and the CTD-ILD group (32). The severity of ILD was evaluated through pulmonary function indicators and the length of hospital stay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum S1P level was statistically higher in ILD patients than in health control (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), while the Serum S1P levels in CTD-ILD and IPF patients were comparable. Serum S1P level further showed statistically negative correlation with pulmonary function indexes (TLC% pred, FVC% pred and FEV1% pred) and positive correlation with length of hospital stay (<jats:italic>r<\/jats:italic> = -0.38, <jats:italic>p<\/jats:italic>\u2009=\u20090.04; <jats:italic>r<\/jats:italic> = -0.41, <jats:italic>p<\/jats:italic>\u2009=\u20090.02, <jats:italic>r<\/jats:italic> = -0.37, <jats:italic>p<\/jats:italic>\u2009=\u20090.04; <jats:italic>r<\/jats:italic>\u2009=\u20090.42, <jats:italic>p<\/jats:italic>\u2009=\u20090.02, respectively) in CTD-ILD patients, although serum S1P level was not significantly correlated with inflammatory indexes. The IPF patients failed to exhibit a significant correlation of serum S1P level with pulmonary function and length of hospital stay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Serum S1P level might be a clinically useful biomarker in evaluating the severity of CTD-ILD patients rather than IPF patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-03081-y","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:07:21Z","timestamp":1717517241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum S1P level in interstitial lung disease (ILD) is a potential biomarker reflecting the severity of pulmonary function"],"prefix":"10.1186","volume":"24","author":[{"given":"Fangping","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"3081_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00009113","volume":"23","author":"KM Antoniou","year":"2014","unstructured":"Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respiratory Review: Official J Eur Respiratory Soc. 2014;23:40\u201354.","journal-title":"Eur Respiratory Review: Official J Eur Respiratory Soc"},{"key":"3081_CR2","doi-asserted-by":"crossref","unstructured":"Maher TM, Nambiar AM, Wells AU. The role of precision medicine in interstitial lung disease. Eur Respir J; 2022.","DOI":"10.1183\/13993003.02146-2021"},{"key":"3081_CR3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"3081_CR4","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.","journal-title":"BMJ"},{"key":"3081_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12890-023-02360-4","volume":"23","author":"F Ding","year":"2023","unstructured":"Ding F, Yang L, Wang Y, Wang J, Ma Y, Jin J. Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function. BMC Pulm Med. 2023;23:68.","journal-title":"BMC Pulm Med"},{"key":"3081_CR6","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.eclinm.2021.101079","volume":"39","author":"KL Lewis","year":"2021","unstructured":"Lewis KL, Helgeson SA, Tatari MM, Mallea JM, Baig HZ, Patel NM. COVID-19 and the effects on pulmonary function following infection: a retrospective analysis. EClinicalMedicine. 2021;39:101079.","journal-title":"EClinicalMedicine"},{"key":"3081_CR7","first-page":"5","volume":"67","author":"JL Miguel-Reyes","year":"2015","unstructured":"Miguel-Reyes JL, Gochicoa-Rangel L, P\u00e9rez-Padilla R, Torre-Bouscoulet L. Functional respiratory assessment in interstitial lung disease. Revista De Investigacion Clinica; organo del Hosp de Enfermedades de la Nutricion. 2015;67:5\u201314.","journal-title":"Revista De Investigacion Clinica; organo del Hosp de Enfermedades de la Nutricion"},{"key":"3081_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm1103","volume":"4","author":"S Spiegel","year":"2003","unstructured":"Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397\u2013407.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3081_CR9","doi-asserted-by":"crossref","unstructured":"Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science; 2019;366.","DOI":"10.1126\/science.aar5551"},{"key":"3081_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/thoraxjnl-2014-206684","volume":"70","author":"LS Huang","year":"2015","unstructured":"Huang LS, Berdyshev EV, Tran JT, Xie L, Chen J, Ebenezer DL, et al. Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy. Thorax. 2015;70:1138\u201348.","journal-title":"Thorax"},{"key":"3081_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/thoraxjnl-2011-200026","volume":"67","author":"J Milara","year":"2012","unstructured":"Milara J, Navarro R, Juan G, Peir\u00f3 T, Serrano A, Ram\u00f3n M, et al. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax. 2012;67:147\u201356.","journal-title":"Thorax"},{"key":"3081_CR12","doi-asserted-by":"publisher","first-page":"35258","DOI":"10.1074\/jbc.M105442200","volume":"276","author":"LC Boujaoude","year":"2001","unstructured":"Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, Hannun YA, et al. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem. 2001;276:35258\u201364.","journal-title":"J Biol Chem"},{"key":"3081_CR13","doi-asserted-by":"crossref","unstructured":"Jayant G, Kuperberg S, Somnay K, Wadgaonkar R. The role of sphingolipids in regulating vascular permeability in idiopathic pulmonary fibrosis. Biomedicines; 2023;11.","DOI":"10.3390\/biomedicines11061728"},{"key":"3081_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jbior.2014.09.008","volume":"57","author":"LS Huang","year":"2015","unstructured":"Huang LS, Natarajan V. Sphingolipids in pulmonary fibrosis. Adv Biol Regul. 2015;57:55\u201363.","journal-title":"Adv Biol Regul"},{"key":"3081_CR15","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"3081_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"3081_CR17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955\u201364.","journal-title":"Ann Rheum Dis"},{"key":"3081_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3081_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3081_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3081_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201907-1343LE","volume":"201","author":"S Alqalyoobi","year":"2020","unstructured":"Alqalyoobi S, Adegunsoye A, Linderholm A, Hrusch C, Cutting C, Ma SF, et al. Circulating plasma biomarkers of progressive interstitial lung disease. Am J Respir Crit Care Med. 2020;201:250\u20133.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03081-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:10:11Z","timestamp":1717517411000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03081-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03081-y","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Chao-Yang Hospital, Capital Medical University (2021-KE-295). This study was conducted in accordance with the principles of the Declaration of Helsinki and the experimental protocol for data involving human followed the Ethical Guidelines of Beijing Chao-Yang Hospital Capital Medical University. The written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, but written informed consent was obtained from the patient for the publication of case report and any accompanying images in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}